Edison Investment Research - Therapix Biosciences ADS (TRPX) Therapix Biosciences - Two new cannabinoid programs

Report

Edison Investment Research

Maxim Jacobs

Therapix Biosciences - Two new cannabinoid programs

Therapix is expanding its cannabinoid-based clinical pipeline beyond neurological disorders to potentially treat obstructive sleep apnea (OSA), a chronic sleep disorder. The company is investigating the efficacy of THX-OSA01, an oral THC/PEA formulation, for the treatment of OSA in a 30-patient Phase IIa trial. In addition, Therapix is exploring the potential of a cannabinoid composition containing an antibacterial agent for the treatment of infectious diseases in preclinical trials. The company reported that the Phase IIa Tourette’s study will read out in H118 and the Phase I for mild cognitive impairment will begin in Q118.

17/11/2017 9 EN

Underlying

Therapix Biosciences ADS

See profile

US88339A2033 Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

Edison Investment Research

Tackling neurology with cannabinoids

Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. It recently listed on NASDAQ in the US 2.3m ADS (worth $13.8m). The lead clinical program, THX-TS01, is currently in Phase II trials testing its potential for treating Tourette’s in adults and THX-ULD01 is scheduled to begin Phase I trials for the treatment of mild cognitive impairment (MCI) in mid-2017. Both programs should qualify for a 505(b)(2) pathway to streamline approval. We arrive at an initial valuation of $38.4m or $10.97 per ADS.

June 29, 2017 June 29, 2017 15 EN

Edison Investment Research

Cannabinoids for underserved diseases

Therapix recently underwent an IPO on NASDAQ in the US of 2.3m ADS (worth $13.8m) to finance the clinical development of cannabinoid products. The lead clinical program, THX-TS01, is a combination of THC, the primary active ingredient in cannabis, and palmitoylethanolamide, a molecule generally regarded as safe, which is approved for use as a health supplement in some parts of Europe and Canada. THX-TS01 is currently in Phase II trials testing its potential for treating Tourette’s in adults. Therapix also has a preclinical program, dubbed THX-ULD01, seeking to treat mild cognitive impairment (...

June 7, 2017 June 7, 2017 2 EN

Norcros - Sale of Johnson Tiles UK agreed

Norcros’s disposal of Johnson Tiles is the latest strategic activity taken by management to better allocate capital to fit with priorities. Last year it closed its UK adhesives operation. Norcros has a compelling investment case, where its new product development initiatives, market positioning and self-help initiatives allow it to take market share in both the UK and South Africa. Its rating is low at 6.0x FY24e P/E, which is attractive, especially when compared to its yield of 5.4% on its well-covered dividend. We retain our estimates and value the shares at 246p, implying c 30% upside.

17h / 4m 17h / 4m 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

19h / 53m 19h / 53m 1 EN

Richard Williamson

Richard Williamson

Freelancer - AI to drive return to growth

Freelancer’s Q124 results were mixed. Operationally, the company is seeing rising demand for AI specialists as customers seek affordable ways to develop proprietary AI. Notably, in Enterprise, the company delivered a large-scale AI pilot for a tech giant, sourcing 20,000 freelancers in 24 hours across 52 languages. This impressive achievement could lead to a substantial multi-year contract. Major initiatives across Loadshift and Escrow with leading organisations are set to be deployed over the coming months, potentially catalysing performance and diversifying revenue streams. We revise our for...

20h / 56m 20h / 56m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Therapix Biosciences - Two new cannabinoid programs

Tackling neurology with cannabinoids

Cannabinoids for underserved diseases

Norcros - Sale of Johnson Tiles UK agreed

Henderson Far East Income - Repositioning to raise total returns

Freelancer - AI to drive return to growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe